Suppr超能文献

β受体阻滞剂作为老年高血压患者一线治疗药物面临的挑战。

Challenges for beta-blockers as first-line therapy for elderly hypertensive patients.

作者信息

Prisant L Michael

机构信息

Hypertension and Clinical Pharmacology, Unit, BI-5084, 1120 Fifteenth St, Medical College of Georgia, Augusta, GA 39012-3105, USA.

出版信息

Postgrad Med. 2002 Dec;112(6 Suppl Heart):34-41. doi: 10.3810/pgm.12.2002.suppl24.129.

Abstract

The prevalence of hypertension increases with age. With aging, many physiologic changes must be considered with treatment. Concerns remain about the appropriateness of beta-blocker therapy in the elderly, even though many of these are unsubstantiated, and evidence exists to support beta-blocker use. A literature search reveals that beta-blockers and nonpharmacologic interventions are effective in the elderly. Although no well-designed, long-term, large-scale, clinical trials exist that assess outcomes for beta-blockers as monotherapy for treating hypertensive elderly patients, this fact should not deter their use in combination therapy, especially for those with comorbid diseases such as angina, myocardial infarction, and heart failure.

摘要

高血压的患病率随年龄增长而增加。随着年龄的增长,治疗时必须考虑许多生理变化。尽管其中许多担忧没有事实依据,但对于老年患者使用β受体阻滞剂治疗的适宜性仍存在担忧,不过也有证据支持使用β受体阻滞剂。文献检索表明,β受体阻滞剂和非药物干预措施对老年人有效。虽然目前尚无精心设计、长期、大规模的临床试验来评估β受体阻滞剂作为单一疗法治疗老年高血压患者的疗效,但这一事实不应妨碍其在联合治疗中的使用,尤其是对于患有心绞痛、心肌梗死和心力衰竭等合并症的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验